PL3830120T3 - NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1 - Google Patents

NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1

Info

Publication number
PL3830120T3
PL3830120T3 PL19746089.2T PL19746089T PL3830120T3 PL 3830120 T3 PL3830120 T3 PL 3830120T3 PL 19746089 T PL19746089 T PL 19746089T PL 3830120 T3 PL3830120 T3 PL 3830120T3
Authority
PL
Poland
Prior art keywords
fusion protein
protein specific
novel fusion
novel
specific
Prior art date
Application number
PL19746089.2T
Other languages
English (en)
Inventor
Marina PAVLIDOU
Lucia PATTARINI
Alix SCHOLER-DAHIREL
Christine Rothe
Shane Olwill
Rachida Bel Aiba
Marlon HINNER
Janet PEPER
Original Assignee
Pieris Pharmaceuticals Gmbh
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh, Les Laboratoires Servier filed Critical Pieris Pharmaceuticals Gmbh
Publication of PL3830120T3 publication Critical patent/PL3830120T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
PL19746089.2T 2018-07-31 2019-07-31 NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1 PL3830120T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18186445 2018-07-31
EP18204548 2018-11-06
PCT/EP2019/070596 WO2020025659A1 (en) 2018-07-31 2019-07-31 Novel fusion protein specific for cd137 and pd-l1

Publications (1)

Publication Number Publication Date
PL3830120T3 true PL3830120T3 (pl) 2023-10-09

Family

ID=67480227

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19746089.2T PL3830120T3 (pl) 2018-07-31 2019-07-31 NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1

Country Status (25)

Country Link
US (1) US20210363257A1 (pl)
EP (2) EP4249064A3 (pl)
KR (1) KR20210040103A (pl)
CN (1) CN112789292A (pl)
AU (1) AU2019315703A1 (pl)
BR (1) BR112020025263A2 (pl)
CA (1) CA3100119A1 (pl)
CL (1) CL2021000207A1 (pl)
CY (1) CY1126148T1 (pl)
DK (1) DK3830120T3 (pl)
ES (1) ES2948717T3 (pl)
FI (1) FI3830120T3 (pl)
HR (1) HRP20230590T2 (pl)
HU (1) HUE062320T2 (pl)
IL (1) IL279541A (pl)
LT (1) LT3830120T (pl)
MD (1) MD3830120T3 (pl)
MX (1) MX2021000401A (pl)
PH (1) PH12021550001A1 (pl)
PL (1) PL3830120T3 (pl)
RS (1) RS64343B9 (pl)
SG (1) SG11202100989UA (pl)
SI (1) SI3830120T1 (pl)
WO (1) WO2020025659A1 (pl)
ZA (1) ZA202100125B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210096640A (ko) * 2018-11-29 2021-08-05 하버 바이오메드 테라푸틱스 리미티드 항-pd-l1 항체 제제
EP4041772A4 (en) 2019-10-11 2024-04-24 Nanjing Leads Biolabs Co Ltd 4-1BB-BINDING ANTIBODIES AND USES THEREOF
KR20230020443A (ko) 2020-06-05 2023-02-10 피어이스 파마슈티컬즈 게엠베하 4-1bb 표적화 다량체 면역조절제
AU2022206035A1 (en) * 2021-01-08 2023-07-20 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
CN114736303A (zh) * 2022-03-17 2022-07-12 英诺湖医药(杭州)有限公司 抗pd-l1和4-1bb的双功能抗体及其医药用途
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
WO2024064713A1 (en) * 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228
CN116211860B (zh) * 2023-05-10 2023-08-22 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
TR200003635T2 (tr) 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
CA2936611A1 (en) * 2014-01-13 2015-07-16 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
US11261221B2 (en) * 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN108112253B (zh) * 2015-05-18 2022-09-23 皮里斯制药有限公司 抗癌融合多肽
IL260530B2 (en) * 2016-01-11 2024-01-01 Inhibrx Inc Multispecific and multivalent 41BB-binding fusion proteins, preparations containing them and their uses
MX2017016851A (es) * 2016-03-04 2018-04-30 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos.
PE20190510A1 (es) * 2016-06-13 2019-04-10 I Mab Anticuerpos anti-pd-l1 y usos de los mismos
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
KR20200041835A (ko) * 2017-09-01 2020-04-22 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 재조합 이중특이적 항체
WO2023000675A1 (zh) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 靶向pd-l1和4-1bb的双特异性抗体

Also Published As

Publication number Publication date
FI3830120T3 (fi) 2023-06-13
IL279541A (en) 2021-01-31
RS64343B1 (sr) 2023-08-31
SG11202100989UA (en) 2021-02-25
US20210363257A1 (en) 2021-11-25
DK3830120T3 (da) 2023-06-26
EP3830120B9 (en) 2023-08-30
CL2021000207A1 (es) 2021-08-13
HUE062320T2 (hu) 2023-10-28
EP3830120B1 (en) 2023-05-24
AU2019315703A1 (en) 2020-12-10
ZA202100125B (en) 2023-06-28
HRP20230590T2 (hr) 2024-02-16
KR20210040103A (ko) 2021-04-12
PH12021550001A1 (en) 2021-09-27
CA3100119A1 (en) 2020-02-06
CN112789292A (zh) 2021-05-11
MD3830120T2 (ro) 2023-08-31
EP4249064A3 (en) 2023-12-06
TW202019967A (zh) 2020-06-01
RS64343B9 (sr) 2023-11-30
EP3830120A1 (en) 2021-06-09
MD3830120T3 (ro) 2023-11-30
ES2948717T3 (es) 2023-09-18
MX2021000401A (es) 2021-03-25
EP4249064A2 (en) 2023-09-27
CY1126148T1 (el) 2023-11-15
WO2020025659A1 (en) 2020-02-06
BR112020025263A2 (pt) 2021-03-09
SI3830120T1 (sl) 2023-10-30
HRP20230590T1 (hr) 2023-09-15
JP2021533203A (ja) 2021-12-02
LT3830120T (lt) 2023-07-10

Similar Documents

Publication Publication Date Title
ZA202100125B (en) Novel fusion protein specific for cd137 and pd-l1
GB2564823B (en) Compositions and methods for TCR reprogramming using fusion proteins
EP3298033A4 (en) Compositions and methods for tcr reprogramming using fusion proteins
EP3348571A4 (en) SINGLE DOMAIN ANTIBODY FOR LIGAND OF PROGRAMMED CELLULAR DEATH RECEPTOR (PD-L1) AND PROTEIN DERIVED THEREFROM
EP3287470A4 (en) Novel recombinant bi-functional fusion protein and preparation and application therefor
EP3280727A4 (en) TYPE I AND SINGLE-ARM TYPE II RECEPTOR FUSION PROTEINS AND USES THEREOF
SG11202012004SA (en) Rna-targeting fusion protein compositions and methods for use
IL284687A (en) Novel fusion proteins specific for CD137 and GPC3
EP3147298A4 (en) Pd-l1 fusion protein and use thereof
EP3880814A4 (en) FUSION PROTEIN
SG11202008721SA (en) Compositions and methods for tcr reprogramming using fusion proteins
EP3757218A4 (en) MERGER PROTEIN
IL287318A (en) Materials and methods for the production of proteins
SG11202101811VA (en) Compositions and methods for tcr reprogramming using fusion proteins
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
ZA202003845B (en) Fusion proteins
IL291236A (en) Compositions and methods for reprogramming tcr using fusion proteins
SG11202000775SA (en) Fusion tags for recombinant protein expression
EP3317297A4 (en) BTLA AGONIST FUSION PROTEIN AND USES THEREOF
IL291284A (en) Systems and methods for expression of proteins
ZA202102533B (en) Fusion protein
EP4034565A4 (en) PD-L1 TARGETED CHIMERIC PROTEINS AND THEIR USES
EP3740501A4 (en) FUSION PROTEIN EXTENSIONS
IL290715A (en) nkg2d fusion proteins and their use
IL281397B (en) Human pd–l1 antibodies